КардиоСоматика (Dec 2013)
Clinical use of the III generation calcium antagonist Amlotopin the treatment of patients with cardiovascular disease
Abstract
Despite the facts, revealing the mechanisms of pathogenesis and enhancing the effectiveness of the treatment of cardiovascular disease (CVD), the latter continues to be the leading cause of death and disability in the population. In this regard, the search for new treatments for CVD remains the most relevant in modern cardiology. In the treatment of CVD many classes of drugs are used, among which are calcium antagonists (AA). This class of drugs has been successfully used in the treatment of patients with arterial hypertension (AH) and coronary heart disease [1-3, 5].CA are a heterogeneous group of drugs that have the similar actionmechanism, but differ in a number of properties, including pharmacokinetics, tissue selectivity, effect on heart rate, etc. The main feature of all is the ability of CA to reversibly inhibit calcium current through the slow calcium channels. These funds are used in cardiology from the end of the 1960s and have since become so widely popular that in most developed countries they hold one of the first places on the prescription rate of drugs used for the treatment of cardiovascular disease. This is due, on the one hand, to the CA high clinical efficacy, and on the other to a relatively small number of contraindications to their purpose and the comparatively small number of side effects. [1, 2, 4, 5].
